Melanotan I vs Melanotan II: What's Actually Different?

Melanotan I and Melanotan II get discussed as if they were two doses of the same thing. They aren't. They're structurally different molecules with different receptor selectivity, and that single distinction accounts for nearly every reported difference between them.

Shared origin

Both are synthetic analogues of alpha-melanocyte-stimulating hormone (α-MSH), the endogenous peptide that signals through the melanocortin receptor family. Five melanocortin receptors are described:

• MC1R — pigmentation, melanocyte biology
• MC2R — adrenal, ACTH signalling
• MC3R / MC4R — energy balance, appetite, sexual function pathways
• MC5R — exocrine gland function

Native α-MSH is degraded rapidly. Both analogues were designed for greater metabolic stability.

Melanotan I (afamelanotide)

A linear, 13-amino-acid α-MSH analogue with relatively selective MC1R activity.

Because it concentrates its activity at MC1R, research interest sits squarely in melanocyte biology and photoprotection models. Afamelanotide has been formally developed as a pharmaceutical for erythropoietic protoporphyria in several jurisdictions — a rare instance of a melanocortin analogue with a genuine regulatory dossier behind it.

Its narrower receptor profile is the reason it is generally described in the literature as the more predictable of the two.

Melanotan II

A cyclic heptapeptide, and non-selective: it acts across MC1R, MC3R, MC4R and MC5R.

That breadth is why Melanotan II appears in a much wider range of research contexts — pigmentation models, appetite and energy-balance signalling, and sexual-function pathways via MC4R. It's also why its effects are harder to isolate. Activating four receptor subtypes at once is a broad intervention, and any observed outcome has several possible attributions.

The MC4R activity is directly relevant to how the melanocortin field developed: bremelanotide (PT-141), a separate approved compound, is a metabolite-derived analogue arising from Melanotan II research.

Side-by-side

• Structure: MT-I linear · MT-II cyclic
• Receptor profile: MT-I selective MC1R · MT-II non-selective MC1R/3R/4R/5R
• Research focus: MT-I pigmentation and photoprotection · MT-II pigmentation, appetite, sexual function
• Interpretability: MT-I narrower and cleaner · MT-II broader and harder to attribute
• Regulatory history: MT-I developed as afamelanotide · MT-II never approved

Why the distinction matters in study design

If a protocol is examining melanocyte response specifically, a non-selective compound introduces confounds you then have to argue away. If the question is melanocortin signalling more broadly, selectivity throws away most of the signal you're looking for.

Choosing the analogue is choosing the hypothesis. Substituting one for the other because they share a name is the fastest way to produce a result nobody can interpret.

EVERKIND stocks Melanotan I 10mg for laboratory research use.

Disclaimer: This article is educational only. All compounds discussed are supplied strictly for laboratory research use and are not approved for human or veterinary use.